Search

Displaying results 1001 - 1010 of 1100 in total
  1. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Inherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471].

  2. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

  3. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measure...

  4. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S

  5. Drug

    Sulfamethoxazole

    go.drugbank.com/drugs/DB01015
    ApprovedInvestigational

    Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic ac...

    Mixtures: Sulfamethoxazole and Trimethoprim for Injection, USP, Sulfamethoxazole and Trimethoprim for Injection, USP
  6. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention

  7. Drug

    Isoniazid

    go.drugbank.com/drugs/DB00951
    ApprovedInvestigational

    Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

    Categories: rifampicin, pyrazinamide, isoniazid and levofloxacin
  8. Drug

    ChulaCov19 mRNA vaccine

    go.drugbank.com/drugs/DB16445
    Experimental

    The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678].

  9. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US

  10. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2...